# EDGAR Filing Document

**Accession Number:** 0001409493
**File Stem:** 0001193125-23-042030
**Filing Date:** 2023-2
**Character Count:** 3708
**Document Hash:** 554c421fd3aff837c05d8576dc0fb42a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-042030.hdr.sgml**: 20230217

**ACCESSION NUMBER**: 0001193125-23-042030

**CONFORMED SUBMISSION TYPE**: 424B5

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230217

**DATE AS OF CHANGE**: 20230217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CHIMERA INVESTMENT CORP
- **CENTRAL INDEX KEY:** 0001409493
- **STANDARD INDUSTRIAL CLASSIFICATION:** REAL ESTATE INVESTMENT TRUSTS [6798]
- **IRS NUMBER:** 260630461
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B5
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-261462
- **FILM NUMBER:** 23643091

**BUSINESS ADDRESS:**
- **STREET 1:** 520 MADISON AVENUE
- **STREET 2:** 32ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 212-626-2300

**MAIL ADDRESS:**
- **STREET 1:** 520 MADISON AVENUE
- **STREET 2:** 32ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

**Filed Pursuant to Rule 424(b)(5)** 

**Registration Statement No. 333-261462** 

**Supplement Dated February 17, 2023** 

**To Prospectus Supplement Dated February 18, 2022** 

**(To Prospectus Dated December 2, 2021)** 

**$500,000,000**![LOGO](g414598g0217014925706.jpg)

------

**Common Stock** 

------

This supplement supplements the prospectus supplement, dated February 18, 2022, relating to shares of our common stock, par value $0.01 per share, or our common stock, offered by this supplement, the prospectus supplement and the accompanying prospectus, pursuant to an "at the market" offering program. In accordance with the terms of the separate distribution agency agreements with the sales agents named therein, each dated February 18, 2022, we may offer and sell shares of our common stock having an aggregate offering price of up to $500,000,000 from time to time through the sales agents and any additional agents appointed under separate distribution agency agreements in the future. Sales of our common stock, if any, under this supplement, the prospectus supplement and the accompanying prospectus may be made in negotiated transactions or transactions that are deemed to be "at the market" offerings, as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on the NYSE or sales made to or through a market maker other than on an exchange. This supplement should be read in conjunction with the prospectus supplement and the accompanying prospectus.

This supplement is being filed to reflect the amendment of the separate distribution agency agreements, each dated February 18, 2022, with JMP Securities LLC, Credit Suisse Securities (USA) LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and RBC Capital Markets, LLC to include J.P. Morgan Securities LLC and UBS Securities LLC as additional sales agent, and the entry into separate distribution agency agreements with J.P. Morgan Securities LLC and UBS Securities LLC as additional sales agents. Accordingly, each reference to the term "sales agent" or "sales agent" in the prospectus supplement is hereby amended to include J.P. Morgan Securities LLC and UBS Securities LLC.

As of the date of this supplement, we have not issued any shares of our common stock through the distribution agency agreements.

------

---

| | | | |
|:---|:---|:---|:---|
| **JMP Securities** | **Credit Suisse** | **Goldman Sachs & Co. LLC** | **J.P. Morgan** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A CITIZENS COMPANY |  |  |  |

---

---

| | | |
|:---|:---|:---|
| **Morgan Stanley** | **RBC Capital Markets** | **UBS Investment Bank** |

---